Arbutus Biopharma (ABUS) Other Non Operating Income (2013 - 2026)
Arbutus Biopharma (ABUS) posted Other Non Operating Income of -$11000.0 for Q1 2026, down 1200.0% sequentially from $1000.0 in Q4 2025, and down 375.0% YoY from $4000.0 in Q1 2025.
Arbutus Biopharma (ABUS) Other Non Operating Income (2013 - 2026) Analysis & Trends
Arbutus Biopharma has reported Other Non Operating Income for 14 years, with the latest figure at -$11000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 375.0% year-over-year to -$11000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1000.0 (up 96.88% YoY) and the FY2025 annual result came in at $14000.0, up 128.57% from the prior year.
- Other Non Operating Income fell to -$11000.0 in Q1 2026 per ABUS's latest filing, from $1000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $21000.0 in Q2 2025 and troughed at -$33000.0 in Q4 2024.
- A 5-year average of -$2687.5 and a median of $1000.0 in 2023 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2023 and 2024: Other Non Operating Income surged 450.0% in 2023, then slumped 900.0% in 2024.
- Over 5 years, Other Non Operating Income stood at -$4000.0 in 2022, then soared by 450.0% to $14000.0 in 2023, then sank by 335.71% to -$33000.0 in 2024, then jumped by 103.03% to $1000.0 in 2025, then plunged by 1200.0% to -$11000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$11000.0, $1000.0, and -$12000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,000.00 |
| Mar 31, 2026 | -11,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | -12,000.00 |
| Jun 30, 2025 | 21,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Dec 31, 2024 | -33,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Jun 30, 2024 | -8,000.00 |
| Mar 31, 2024 | -13,000.00 |
| Dec 31, 2023 | 14,000.00 |
| Sep 30, 2023 | 6,000.00 |
| Jun 30, 2023 | 1,000.00 |
| Mar 31, 2023 | 4,000.00 |
| Dec 31, 2022 | -4,000.00 |
| Sep 30, 2022 | -21,000.00 |
| Jun 30, 2022 | 3,000.00 |
| Dec 31, 2021 | 5,000.00 |
| Sep 30, 2021 | -15,000.00 |
| Jun 30, 2021 | -13,000.00 |